Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Primary brain tumors are predominantly malignant gliomas. Grade IV astrocytomas (glioblastomas, GBM) are among the most deadly of all tumors; most patients will succumb to their disease within 2 years of diagnosis despite standard of care. The grim outlook for brain tumor patients indicates that novel precision therapeutic targets must be identified. Our hypothesis is that the cancer proteomes of glioma tumors may contain protein variants that are linked to the aggressive pathology of the disease. To this end, we devised a novel workflow that combined variant proteomics with molecular epidemiological mining of public cancer data sets to identify 10 previously unrecognized variants linked to the risk of death in low grade glioma or GBM. We hypothesize that a subset of the protein variants may be successfully developed in the future as novel targets for malignant gliomas.

Detaljer

Författare
  • Ekaterina Mostovenko
  • Yanhong Liu
  • E. Susan Amirian
  • Spiridon Tsavachidis
  • Georgina N. Armstrong
  • Melissa L. Bondy
  • Carol L. Nilsson
Enheter & grupper
Externa organisationer
  • Virginia Commonwealth University
  • Baylor College of Medicine
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
  • Läkemedelskemi

Nyckelord

Originalspråkengelska
Sidor (från-till)80-84
Antal sidor5
TidskriftACS Chemical Neuroscience
Volym9
Utgivningsnummer1
StatusPublished - 2018 jan 17
PublikationskategoriForskning
Peer review utfördJa